Clinical trials
Locally Advanced Head and Neck Squamous Cell Carcinoma clinical trials
Below are recruiting locally advanced head and neck squamous cell carcinoma clinical trials, each written for real people, not researchers. We’re tracking 187 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05668858RecruitingPhase 1/Phase 2
Test antibodies plus or minus chemo for advanced head and neck cancer
This early-phase study tests a combination of antibody medicines (with optional chemotherapy) in people with advanced or metastatic head and neck squamous cell carcinoma. The goal is to see how well the treatment controls the cancer and what side effects are like.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05706129RecruitingPhase 1/Phase 2
Testing targeted imaging and therapy for advanced solid tumors
This early-phase study tests two radioactive medicines that first help doctors see tumors and, in some parts of the study, treat them. It may help people with advanced, hard-to-remove cancers that have a specific tumor marker (CA IX).
MelbourneAges 18 years+ - NCT05710679Recruiting
Blood test predicts leftover cancer after intensified head and neck radiation
This study uses a blood test to see whether cancer DNA is still detectable after a stronger combination of radiation and chemotherapy for locally advanced head and neck cancer. The goal is to predict who may have “residual” (remaining) disease and help guide future care.
Clermont-Ferrand, Puy-de-DômeAges 18–80 - NCT05758389RecruitingPhase 2
Immunotherapy plus chemo for locally advanced head and neck cancer
This Phase 2 study tests whether tislelizumab (an immunotherapy) combined with chemotherapy works better for locally advanced head and neck squamous cell cancer. It aims to improve cancer control when the tumor is large and has not spread to distant organs.
Nanjing, JiangsuAges 18–75 - NCT05784688RecruitingPhase 1/Phase 2
TU2218 with Keytruda for advanced solid tumors
This trial studies TU2218 taken with Keytruda (pembrolizumab) in adults with advanced solid cancers that have limited treatment options. The goal is to see if the combination can shrink tumors and is safe enough to keep using.
San Antonio, TexasAges 18 years+ - NCT05854823Recruiting
Reduced radiation after surgery for advanced head and neck cancer
This trial looks at whether giving less (de-escalated) radiation after surgery is as effective and safer for people with locally advanced head and neck squamous cell carcinoma who had a strong response to treatment before surgery. If you had no remaining cancer or only very small amounts of cancer left in the surgical specimen, this approach may help reduce side effects while keeping control of the disease.
Zhuhai, GuangdongAges 18–70 - NCT05862168RecruitingPhase 2
Tislelizumab with chemotherapy before surgery for oral cancer
This trial studies giving tislelizumab (an immune treatment) plus chemotherapy before surgery to shrink and treat locally advanced oral squamous cell cancer. It aims to improve tumor response and outcomes, while checking safety.
HangzhouAges 18–75 - NCT05872880Recruiting
Oral cancer treatment with chemo, then surgery and radiation
This trial studies giving chemotherapy first, then removing the tumor with surgery and follow-up radiation for certain cases of oral squamous cell carcinoma. It may help shrink and control the cancer before and after surgery, depending on how well the tumor can be fully removed.
Changsha, HunanAges 18–65 - NCT05910827RecruitingPhase 1/Phase 2
Study of a HER3 antibody with cetuximab and possibly docetaxel
This Phase 1/2 trial tests whether an antibody that targets HER3 (with cetuximab, and possibly docetaxel) can help treat advanced squamous cell cancers that have already been treated or cannot use standard options. It mainly looks at safety first, and also whether the treatment can shrink tumors.
Sydney, New South WalesAges 18 years+ - NCT05941338RecruitingPhase 2
Tirelizumab plus chemotherapy before head and neck surgery
This Phase 2 trial tests tirelizumab combined with two chemotherapy medicines before surgery for certain head and neck squamous cell cancers. It aims to shrink the tumor and improve outcomes after the operation.
Guangzhou, GuangdongAges 18–65 - NCT05983432RecruitingPhase 1
Study of BL-B01D1 for advanced lung and other solid tumors
This trial tests an experimental drug called BL-B01D1 for people with several types of advanced solid tumors, especially non-small cell lung cancer and breast cancer. It's designed for those whose cancer has continued to grow after standard treatments.
Beverly Hills, CaliforniaAges 18 years+ - NCT06005324RecruitingPhase 1
Personalized treatment for advanced head and neck cancer
This trial tests a custom treatment plan for people with advanced head and neck cancer that is not caused by HPV. It combines radiation and chemotherapy with a targeted drug called cetuximab, adjusted based on your tumor's characteristics.
Chicago, IllinoisAges 18 years+ - NCT06016920RecruitingPhase 1/Phase 2
HPV16 vaccine plus Keytruda for oropharyngeal cancer
This trial tests a new vaccine (VB10.16) combined with the immunotherapy Keytruda (pembrolizumab) for people with HPV16-positive oropharyngeal cancer that has spread or come back. The goal is to see if the combination helps shrink tumors or slow cancer growth.
OlomoucAges 18 years+ - NCT06052839RecruitingPhase 2
Pulsed chemo plus pembrolizumab for head and neck cancer
This trial tests a new way to give chemotherapy (pulsed doses) together with pembrolizumab (an immunotherapy) for people with head and neck cancer that has come back or spread and cannot be cured with local treatments. The goal is to see if this combination works better than standard approaches.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06064877RecruitingPhase 3
Study of ficlatuzumab plus cetuximab for advanced head and neck cancer
This trial tests a combination of two drugs, ficlatuzumab and cetuximab, for people with recurrent or metastatic head and neck cancer that is HPV-negative and has not responded to prior immunotherapy and chemotherapy. It aims to see if this combination can help shrink tumors or slow the disease.
Gilbert, ArizonaAges 18 years+ - NCT06100497RecruitingPhase 2
PD-1 plus chemo for advanced head and neck cancer
This trial tests a combination of immunotherapy (PD-1) and chemotherapy for people with advanced head and neck cancers that are poorly differentiated. The goal is to see if the combination helps shrink tumors before possible surgery or radiation.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06102395RecruitingPhase 3
Pembrolizumab plus chemo before surgery for advanced head and neck cancer
This trial tests whether adding pembrolizumab (an immunotherapy drug) to standard chemotherapy before surgery can help people with advanced head and neck cancer. It aims to see if the combination is more effective than chemotherapy alone.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06129864RecruitingPhase 3
Study of Volrustomig for advanced head and neck cancer after chemoradiation
This trial tests a new drug called volrustomig (MEDI5752) for people with advanced head and neck cancer that was not removed by surgery and has been treated with chemoradiation. The goal is to see if the drug can help prevent the cancer from coming back.
Birmingham, AlabamaAges 18–130 - NCT06172478RecruitingPhase 2
HER3-DXd for advanced solid tumors after prior treatment
This trial tests a new targeted drug called HER3-DXd for people with several types of advanced solid tumors that have stopped responding to standard treatments. The drug is an antibody-drug conjugate, designed to deliver chemotherapy directly to cancer cells that have a protein called HER3 on their surface.
Duarte, CaliforniaAges 18 years+ - NCT06194656RecruitingPhase 2
Trial of SIBP-03 for advanced head and neck cancer
This trial tests a new drug called SIBP-03 for people with head and neck squamous cell carcinoma that has come back or spread. It is for those whose cancer has worsened after prior immunotherapy and platinum chemotherapy, and who have no option for curative local treatment.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06208826RecruitingPhase 2
Immunotherapy maintenance after surgery for head and neck cancer
This trial looks at whether continuing immunotherapy can help keep cancer from coming back in people with head and neck cancer who had a good response to chemo-immunotherapy before surgery. You would have already had surgery, and now the study tests a maintenance treatment to strengthen your immune system's fight against any remaining cancer cells.
Tianjin, Tianjin MunicipalityAges 18–80 - NCT06240689RecruitingPhase 2
Immune maintenance therapy after chemoradiotherapy for head and neck cancer
This trial tests whether adding an immune checkpoint inhibitor (a drug that helps your immune system fight cancer) as maintenance therapy after chemoradiotherapy improves outcomes for people with locally advanced head and neck cancer. It specifically looks at a marker in your blood (CD8Tex cells) to see if you might benefit.
Hangzhou, ZhejiangAges 18–75 - NCT06242470RecruitingPhase 1
Study of MGC026 for advanced solid tumors
This trial tests a new drug called MGC026 that targets a protein called B7-H3 on cancer cells, aiming to shrink or slow different advanced solid tumors. It is an early-phase study to find the right dose and check safety.
Los Angeles, CaliforniaAges 18 years+ - NCT06256588RecruitingPhase 3
Dostarlimab vs placebo after chemoradiation for head and neck cancer
This study tests whether the immunotherapy drug dostarlimab, given after standard chemoradiation, can keep advanced head and neck cancer from coming back. It is for people who have not had surgery and whose tumors are PD-L1 positive.
Jonesboro, ArkansasAges 18 years+
Hear when a new Locally Advanced Head and Neck Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for locally advanced head and neck squamous cell carcinoma?
- Yes. Clin2 currently lists 187 recruiting locally advanced head and neck squamous cell carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a locally advanced head and neck squamous cell carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a locally advanced head and neck squamous cell carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Advanced Head and Neck Squamous Cell Carcinoma
- Locally Recurrent Head and Neck Squamous Cell Carcinoma
- Head and Neck Squamous Cell Carcinoma
- Recurrent Head and Neck Squamous Cell Carcinoma
- Metastatic Head and Neck Squamous Cell Carcinoma
- Head and Neck Cancer Squamous Cell Carcinoma
- Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
- Locally Advanced Esophageal Squamous Cell Carcinoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.